NCT05586243

MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 5 (estimated)
• Sponsor: University of Minnesota · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: —

Summary

Recent studies have has shown that magnetic resonance spectroscopy (MRS) can provide validated neuronal markers in patients with Type 1 GD (GD1) who are on stable therapy. However, alterations in neurometabolites in adult patients with GD3, who have established neurological involvement, are not well understood. The goal of this study is to characterize neurometabolite profiles in adult patients with GD3 using MRS to identify novel biomarkers that can demonstrate treatment response. Additionally, a secondary aim is to evaluate relationships between neurometabolites and disease parameters, such as genotype, enzyme levels and Gaucher disease (GD) biomarkers.

Conditions

• Gaucher Disease, Type 3

Interventions

Type	Name	Description
OTHER	No intervention	This is an observational study looking at brain chemicals related to oxidative stress and inflammation using magnetic resonance spectroscopy (MRS).

Timeline

• Start date: 2023-01-01
• Primary completion: 2026-07-31
• Completion: 2026-07-31
• First posted: 2022-10-19
• Last updated: 2026-01-08

Locations

1 site across 1 country: United States